These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30275274)

  • 21. Immunotherapy-associated autoimmune hemolytic anemia.
    Khan U; Ali F; Khurram MS; Zaka A; Hadid T
    J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
    Hsu JC; Lin JY; Hsu MY; Lin PC
    PLoS One; 2018; 13(8):e0202725. PubMed ID: 30142174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events.
    Albayda J; Bingham CO; Shah AA; Kelly RJ; Cappelli L
    Rheumatology (Oxford); 2018 Apr; 57(4):760-762. PubMed ID: 29342300
    [No Abstract]   [Full Text] [Related]  

  • 24. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN; Kudinov AE; Dulaimi E; Boumber Y
    BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy.
    Cooper DS; Meriggioli MN; Bonomi PD; Malik R
    J Neuromuscul Dis; 2017; 4(2):169-173. PubMed ID: 28505981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-induced Pancreatic Atrophy ("The Vanishing Pancreas").
    Khamaysi I; Hajj E
    Euroasian J Hepatogastroenterol; 2020; 10(2):101-102. PubMed ID: 33511073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
    Papouin B; Mussini C; De Martin E; Guettier C
    Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
    Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
    Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients.
    Yanai S; Nakamura S; Kawasaki K; Toya Y; Akasaka R; Oizumi T; Ishida K; Sugai T; Matsumoto T
    Dig Endosc; 2020 May; 32(4):616-620. PubMed ID: 31595568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
    Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
    J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication.
    Michot JM; Ragou P; Carbonnel F; Champiat S; Voisin AL; Mateus C; Lambotte O; Annereau M
    J Immunother; 2018; 41(2):84-85. PubMed ID: 29252914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nivolumab-induced aplastic anemia: A case report and literature review.
    Comito RR; Badu LA; Forcello N
    J Oncol Pharm Pract; 2019 Jan; 25(1):221-225. PubMed ID: 28825374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
    Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME
    Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bullous Pemphigoid Associated With a New Combination Checkpoint Inhibitor Immunotherapy.
    Fontecilla NM; Khanna T; Bayan CY; Antonov NA; Geskin LJ
    J Drugs Dermatol; 2019 Jan; 18(1):103-104. PubMed ID: 30681807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors).
    Wu Y; Ju Q; Jia K; Yu J; Shi H; Wu H; Jiang M
    Int J Cancer; 2018 Jul; 143(1):45-51. PubMed ID: 29424425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.
    Huffman BM; Kottschade LA; Kamath PS; Markovic SN
    Am J Clin Oncol; 2018 Aug; 41(8):760-765. PubMed ID: 28749795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors].
    Faviez G; Bousquet E; Rabeau A; Rouquette I; Collot S; Goumarre C; Meyer N; Prevot G; Mazieres J
    Rev Mal Respir; 2018 Nov; 35(9):963-967. PubMed ID: 30220489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.